0
0
6/24/25 at 8:23pm
Organization
Investor's Business Daily
30 words
0
Comments
The company's experimental eczema drug met all the primary and secondary goals in a midstage study.
You are the first to view
https://www.investors.com/news/technology/nektar-therapeutics-stock-atopic-dermatitis-treatment-eczema/
Create an account
or login to join the discussion